List of Contents
What is the Cancer Biopsy Market Size?
The global cancer biopsy market size is accounted at USD 36.55 billion in 2025 and predicted to increase from USD 43.42 billion in 2026 to approximately USD 196.68 billion by 2035, representing a CAGR of 18.33% from 2026 to 2035.
Cancer Biopsy Market Key Takeaways
- North America led the global market with the highest market share of 47% in 2025.
- By type, the tissue biopsy segment is estimated to capture the biggest revenue share in 2025.
- By type, the liquid biopsy segment is anticipated to grow at a remarkable CAGR between 2026 and 2035.
- By product, the kits and consumables segment is predicted to register the maximum market share of 61% in 2025.
- By application, the breast cancer segment is estimated to hold the highest market share in 2025.
Cancer Biopsy Market Growth Factors
The removal of tissue for the purpose of examining it for disease is known as a biopsy. Any region of the body can be used to collect tissue samples. Biopsies can be done in a variety of methods. Some biopsies entail taking a little bit of tissue with a needle, while others entail surgically removing a suspected lump or nodule. The imaging tests like MRIs and CT scans can assist detect lumps or abnormal tissue, but they cannot distinguish the difference between cancerous and non-cancerous cells. The only approach to diagnose most malignancies is to take a biopsy and collect cells for further analysis.
The growing elderly population, together with the rising prevalence of cancer indications, is likely to drive the cancer biopsy market expansion. Furthermore, the introduction of liquid biopsy procedures is projected to boost the cancer biopsy market forward. In the field of oncology diagnostics, many procedures such as skin, needle, bone marrow, endoscopic, and surgical biopsies are used on a large scale. The needles biopsies are regarded a favored tool for early detection of patients among these techniques. However, benefits of fine needle aspiration needle biopsies, such as reduced invasion and faster results, have the cancer biopsy market expansion.
The liquid biopsy for cancer diagnosis, prognosis, screening, and treatment has increased competition and capabilities in the cancer biopsy market significantly. The key market players are taking significant steps to enter the cancer biopsy market and are conducting liquid biopsies, which are projected to drive the cancer biopsy market's growth in clinical settings. The liquid biopsy is being utilized to diagnose advanced cancer in individuals who are unable to undergo a tissue biopsy.
The liquid biopsy can also be used to determine targeted therapy or clinical trial eligibility for patients for whom tissue-based testing is not appropriate or available. The liquid biopsy provides oncologists with real-time information about a tumor and is a quick, minimally invasive, and cost-effective diagnostic. These tests have the potential to reveal residual tumor cells, early recurrence diagnosis, and treatment efficacy.
While the issues connected with cancer biopsy pose significant obstacles for technology vendors, laboratories, and clinicians, patients who want to avoid the genuine hazards, potential pain, and high costs associated with tissue biopsy have a strong demand for liquid biopsy. Furthermore, the ability to track treatments and detect disorder early, as well as collect data across the tumor, gives patients a better chance of receiving appropriately targeted therapy.
In terms of instruments, kits, and consumables, cancer biopsy has seen a number of technological advancements. The development of effective products associated with biopsies is critical as liquid biopsy becomes a multimodal tool of diagnosis in the field of clinical oncology. Despite the fact that existing instruments are widely utilized, they have a number of flaws. The introduction of new technologies, on the other hand, is predicted to dramatically enhance the need for instruments in the coming years. Several new companies are concentrating on developing equipment that can improve endoscopy-based biopsies.
Cancer Biopsy Market Outlook
The start-up is going through a prominent growth with its deep understanding and value-added initiative to drive technological advancement appropriately in liquid biopsies, and the artificial intelligence is a popular new reason for the start-up to experience a top position in the cancer biopsy sector to further introduce personalised diagnostic solutions and reduce invasive procedures for excellent treatment outcomes and earlier detection.
The industrial growth of cancer biopsy is prominently characterised by the increased cancer condition and technological advancements, such as liquid biopsy and the latest in demand, personalised medicine. With the urgency of liquid biopsies and accelerating screening and awareness programs, the market has received an extreme positive push to understand new treatments and scenarios influencing oncology.
Market Scope
| Report Coverage | Details |
| Market Size in 2025 | USD 36.55 Billion |
| Market Size in 2026 | USD 43.42 Billion |
| Market Size by 2035 | USD 196.68 Billion |
| Growth Rate from 2026 to 2035 | CAGR of 18.33% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | Type, Product, Application, and Regions |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Cancer Biopsy Market Segment Insights
Type Insights
The tissue biopsy had the highest revenue share in 2025. It is still widely used in biopsies and is widely used across a variety of cancer diagnosis applications. This is due to the rigorous research operations testing its safety and efficacy, which have helped to the expansion of this segment.
The liquid biopsy segment is fastest growing segment of the cancer biopsy market in 2024. In recent years, there has been an increase in physician preference for liquid biopsy, which is bolstered by its capacity to provide disease assessments from both the primary and distant tumor locations. This method is used in personalized medicine treatment, where tumor makers are sampled regularly to adjust the treatment based on the patient's response.
Product Insights
The kits and consumables segment dominated the cancer biopsy market in 2025. The segment's expansion has been aided significantly by large investments made by major market players in the industry.
The instruments segment, on the other hand, is predicted to develop at a rapid rate over the projection period. The rise of the market is related to an increase in the number of patients around the world who require precise, efficient, and quick tools and kits.
Application Insights
In 2025, the breast cancer segment dominated the cancer biopsy market. The growing number of patients suspected of having breast cancer undergoes microscopic study of breast tissue, which is required for obtaining a clear diagnosis, as well as determining the stage and type.
The prostate cancer segment, on the other hand, is predicted to develop at the quickest rate in the future years. The liquid biopsies based on circulating tumor cells can track the minimal residual disease in non-metastatic prostate cancer patients, as well as the follow up examinations, to provide independent prognostic insights.
Cancer Biopsy Market Regional Insights
The U.S. cancer biopsy market size is exhibited at USD 10.55 billion in 2025 and is projected to be worth around USD 57.82 billion by 2035, growing at a CAGR of 18.54% from 2026 to 2035.
North America dominated the cancer biopsy market in 2025. The North America region is expected to maintain its lead during the projected period, with the U.S. contributing significantly to regional revenue. Furthermore, distributors and manufacturers in this region are working to sale and manufacture unique kits that are well-suited for quick diagnostic applications.
Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period. The number of lung cancer cases detected in Asia has increased due to rising awareness among patients and healthcare professionals.
The region's advancement is collectively focusing on liquid biopsies, embedding robotic assistance and artificial intelligence (AI), and minimally invasive techniques to achieve patient outcomes, precision and efficiency. Europe's liquid Biopsy technology is an important leader in unifying and establishing liquid biopsy into clinical practice. The projects such as SHINE and the European Liquid Biopsy Society (ELBS) ling supported the growth of the Cancer Biopsy market.
The transformative move of Latin America is represented by its largely accepted next-generation sequencing (NGS) and different molecular profiling techniques that stimulate the growth of precision oncology. This adoption is significantly highlighting the region as more than its traditional pathology methods to the most precise molecular and genetically of tumors. After the molecular and genomic testing, the liquid biopsies are also leading in the region.
Cancer Biopsy Market Value Chain Analysis
The analysis of the primary stage includes the main biopsy procedure, which is a key, serious point to be performed accurately to justify sample quality. The sample procurement analysis involves logistics, minimally invasive techniques (MIT) and standardisation of procedures. This whole chain consists of the quality and consistency in the sample handling and collection to carry out other secondary procedures with accuracy. The MIT evaluates cost-effectiveness and value of methods such as ctDNA and CTCs.
Sample operations analysis involves pathology workflows, quality control (QC), technology adoption, fixation and preservation. The assessment of the cost and effectiveness of several collection tubes and fixatives avoids degradation. The technology is a justification for the advanced analytical technologies.
The service involves treatment guidance and clinical application to utilise the biopsy results to convey them to the cancer management team. The prognosis evaluation with the help of biomarkers to forecast patient outcome and analyse the risk of recurrence is required to continue with the procedure.
Cancer Biopsy Market Companies
- Myriad Genetics Inc.
- Guardant Health Inc.
- Exact Sciences Corporation
- Bio-Rad Laboratories Inc.
- Agena Bioscience Inc.
- Personal Genome Diagnostics Inc.
- Exosome Diagnostics Inc.
- ANGLE Plc.
- F. Hoffmann-La Roche Ltd.
Recent Developments
- Guardant Health Inc. and MD Anderson established an agreement in January 2017 to make complete liquid biopsy a standard of care in cancer.
- Illumina Inc. reported in March 2021 that their NextSeq 550Dx platform and accompanying reagent kits had received medical device registration in Russia. Prior to this registration, the MiSeq Dx had already been approved as a medical device.
Cancer Biopsy Market Segments Covered in the Report
By Product
- Instruments
- Kits and Consumables
- Services
By Type
- Tissue Biopsies
- Fine Needle Aspiration (FNA)
- Core Needle Biopsy (CNB)
- Needle Biopsies
- Surgical Biopsies
- Liquid Biopsies
- Others
By Application
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Lung Cancer
- Prostate Cancer
- Skin Cancer
- Blood Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
Frequently Asked Questions
Ask For Sample
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client